220 related articles for article (PubMed ID: 30022036)
1. Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study.
Figueroa-Bonaparte S; Llauger J; Segovia S; Belmonte I; Pedrosa I; Montiel E; Montesinos P; Sánchez-González J; Alonso-Jiménez A; Gallardo E; Illa I; ; Díaz-Manera J
Sci Rep; 2018 Jul; 8(1):10898. PubMed ID: 30022036
[TBL] [Abstract][Full Text] [Related]
2. Follow-up of late-onset Pompe disease patients with muscle magnetic resonance imaging reveals increase in fat replacement in skeletal muscles.
Nuñez-Peralta C; Alonso-Pérez J; Llauger J; Segovia S; Montesinos P; Belmonte I; Pedrosa I; Montiel E; Alonso-Jiménez A; Sánchez-González J; Martínez-Noguera A; Illa I; Díaz-Manera J
J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):1032-1046. PubMed ID: 32129012
[TBL] [Abstract][Full Text] [Related]
3. Late-onset Pompe disease (LOPD): correlations between respiratory muscles CT and MRI features and pulmonary function.
Gaeta M; Barca E; Ruggeri P; Minutoli F; Rodolico C; Mazziotti S; Milardi D; Musumeci O; Toscano A
Mol Genet Metab; 2013 Nov; 110(3):290-6. PubMed ID: 23916420
[TBL] [Abstract][Full Text] [Related]
4. Whole-body magnetic resonance imaging in late-onset Pompe disease: Clinical utility and correlation with functional measures.
Khan AA; Boggs T; Bowling M; Austin S; Stefanescu M; Case L; Kishnani PS
J Inherit Metab Dis; 2020 May; 43(3):549-557. PubMed ID: 31710733
[TBL] [Abstract][Full Text] [Related]
5. Study of the effect of anti-rhGAA antibodies at low and intermediate titers in late onset Pompe patients treated with ERT.
Fernández-Simón E; Carrasco-Rozas A; Gallardo E; González-Quereda L; Alonso-Pérez J; Belmonte I; Pedrosa-Hernández I; Montiel E; Segovia S; Suárez-Calvet X; Llauger J; Mayos M; Illa I; Barba-Romero MA; Barcena J; Paradas C; Carzorla MR; Creus C; Coll-Cantí J; Díaz M; Domínguez C; Fernández-Torrón R; García-Antelo MJ; Grau JM; López de Munáin A; Martínez-García FA; Morgado Y; Moreno A; Morís G; Muñoz-Blanco MA; Nascimento A; Parajuá-Pozo JL; Querol L; Rojas R; Robledo-Strauss A; Rojas-Marcos Í; Salazar JA; Usón M; Díaz-Manera J
Mol Genet Metab; 2019; 128(1-2):129-136. PubMed ID: 31378569
[TBL] [Abstract][Full Text] [Related]
6. Correlation between quantitative whole-body muscle magnetic resonance imaging and clinical muscle weakness in Pompe disease.
Horvath JJ; Austin SL; Case LE; Greene KB; Jones HN; Soher BJ; Kishnani PS; Bashir MR
Muscle Nerve; 2015 May; 51(5):722-30. PubMed ID: 25155446
[TBL] [Abstract][Full Text] [Related]
7. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pathophysiological clues of respiratory dysfunction in late-onset Pompe disease: New insights from a comparative study by MRI and respiratory function assessment.
Gaeta M; Musumeci O; Mondello S; Ruggeri P; Montagnese F; Cucinotta M; Vinci S; Milardi D; Toscano A
Neuromuscul Disord; 2015 Nov; 25(11):852-8. PubMed ID: 26410244
[TBL] [Abstract][Full Text] [Related]
9. The nature of respiratory muscle weakness in patients with late-onset Pompe disease.
Spiesshoefer J; Henke C; Kabitz HJ; Brix T; Görlich D; Herkenrath S; Randerath W; Young P; Boentert M
Neuromuscul Disord; 2019 Aug; 29(8):618-627. PubMed ID: 31327549
[TBL] [Abstract][Full Text] [Related]
10. Skeletal muscle magnetic resonance imaging in Pompe disease.
Díaz-Manera J; Walter G; Straub V
Muscle Nerve; 2021 May; 63(5):640-650. PubMed ID: 33155691
[TBL] [Abstract][Full Text] [Related]
11. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.
Montagnese F; Barca E; Musumeci O; Mondello S; Migliorato A; Ciranni A; Rodolico C; De Filippi P; Danesino C; Toscano A
J Neurol; 2015; 262(4):968-78. PubMed ID: 25673129
[TBL] [Abstract][Full Text] [Related]
12. The emerging phenotype of late-onset Pompe disease: A systematic literature review.
Chan J; Desai AK; Kazi ZB; Corey K; Austin S; Hobson-Webb LD; Case LE; Jones HN; Kishnani PS
Mol Genet Metab; 2017 Mar; 120(3):163-172. PubMed ID: 28185884
[TBL] [Abstract][Full Text] [Related]
13. Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy.
Gruhn KM; Heyer CM; Güttsches AK; Rehmann R; Nicolas V; Schmidt-Wilcke T; Tegenthoff M; Vorgerd M; Kley RA
Mol Genet Metab Rep; 2015 Jun; 3():58-64. PubMed ID: 26937398
[TBL] [Abstract][Full Text] [Related]
14. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
[TBL] [Abstract][Full Text] [Related]
15. Dynamic respiratory muscle function in late-onset Pompe disease.
Smith BK; Allen S; Mays S; Martin AD; Byrne BJ
Sci Rep; 2019 Dec; 9(1):19006. PubMed ID: 31831753
[TBL] [Abstract][Full Text] [Related]
16. Quantification of intramuscular fat in patients with late-onset Pompe disease by conventional magnetic resonance imaging for the long-term follow-up of enzyme replacement therapy.
Lollert A; Stihl C; Hötker AM; Mengel E; König J; Laudemann K; Gökce S; Düber C; Staatz G
PLoS One; 2018; 13(1):e0190784. PubMed ID: 29315315
[TBL] [Abstract][Full Text] [Related]
17. White matter lesions in treated late onset Pompe disease are not different to matched controls.
Schneider I; Hensel O; Zierz S
Mol Genet Metab; 2019 Jun; 127(2):128-131. PubMed ID: 31153821
[TBL] [Abstract][Full Text] [Related]
18. Treatment Dilemma in Children with Late-Onset Pompe Disease.
Faraguna MC; Crescitelli V; Fornari A; Barzaghi S; Savasta S; Foiadelli T; Veraldi D; Paoletti M; Pichiecchio A; Gasperini S
Genes (Basel); 2023 Jan; 14(2):. PubMed ID: 36833288
[TBL] [Abstract][Full Text] [Related]
19. Central nervous system involvement in late-onset Pompe disease: clues from neuroimaging and neuropsychological analysis.
Musumeci O; Marino S; Granata F; Morabito R; Bonanno L; Brizzi T; Lo Buono V; Corallo F; Longo M; Toscano A
Eur J Neurol; 2019 Mar; 26(3):442-e35. PubMed ID: 30312517
[TBL] [Abstract][Full Text] [Related]
20. The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients.
Feeney EJ; Austin S; Chien YH; Mandel H; Schoser B; Prater S; Hwu WL; Ralston E; Kishnani PS; Raben N
Acta Neuropathol Commun; 2014 Jan; 2():2. PubMed ID: 24383498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
